# Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

> **NCT00009750** · PHASE1 · UNKNOWN · sponsor: **University of California, Davis**

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** monoclonal antibody m170
- **DRUG:** cyclosporine
- **DRUG:** paclitaxel
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** indium In 111 monoclonal antibody m170
- **RADIATION:** yttrium Y 90 monoclonal antibody m170

## Key facts

- **NCT ID:** NCT00009750
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00009750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00009750, "Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00009750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*